Klinische studies over pulmonale hypertensie

Actieve rekrutering

  • ADVANCE OUTCOMES: A Study Evaluating the Efficacy and Safety of Ralinepag to Improve Treatment Outcomes in PAH Patients (Ralinepag/placebo).
  • ADVANCE EXTENSION: A Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension.
  • COMPERA REGISTER: Prospective registry of newly initiated therapies for pulmonary hypertension.
  • SALTO: A Study of Selexipag as Add-On Treatment to Standard of Care in Children With Pulmonary Arterial Hypertension.
  • SELECT: A Study to Find Out if Selexipag is Effective and Safe in Patients With Chronic Thromboembolic Pulmonary Hypertension When the Disease is Inoperable or Persistent/Recurrent After Surgery and/or Interventional Treatment.
  • SPHYNX: A Study in Participants With Sarcoidosis-associated Pulmonary Hypertension (SAPH) to Assess the Efficacy and Safety of Oral Selexipag.
  • UNISUS: Outcome Study Assessing a 75 Milligrams (mg) Dose of Macitentan in Patients With Pulmonary Arterial Hypertension.

Toekomstige studies

  • ADVANCE CAPACITY: A Study of Ralinepag to Evaluate Effects on Exercise Capacity by CPET in Subjects With WHO Group 1 PH.
  • CIPHER: A Study for the Identification of Biomarker Signatures for Early Detection of Pulmonary Hypertension (PH).
  • ELEVATE 1: A Study of RVT-1201 in Patients With Pulmonary Arterial Hypertension.
  • Exposure: Post-authorisation safety study (PASS): observational cohort study of PAH patients newly treated with either Uptravi® (selexipag) or any other PAH-specific therapy, in clinical practice.
  • GB002: Clinical Study of Inhaled GB002 for Treatment of WHO Group I Pulmonary Arterial Hypertension (PAH).
  • STELLAR: A Study of Sotatercept for the Treatment of Pulmonary Arterial Hypertension.
  • UMBRELLA: A Clinical Study to Investigate the Long-term Safety of the Drug Macitentan in Patients With Pulmonary Hypertension Who Were Previously Treated With Macitentan in Clinical Studies.

Contact

Centrum pulmonale hypertensie
Laatste aanpassing: 27 januari 2021